April 8, 2019 – March 31, 2020

44,793

# A. PERSONNELB. MANDATORY FRINGE

 2.10 0943 – Manager VIII: Susan Buchbinder Annual Salary \$189,600 x 2.1 FTE for 12 months = 33,180 Mandatory Fringe Benefits (@ 35%) = 11,613

Dr. Buchbinder as Principal Investigator (PI) of this proposal, she will be responsible for the overall scientific vision and implementation of the specific aims of this study. Dr. Buchbinder will have responsibility for maintaining the proposed study schedule, ensuring quality control over all aspects of the study, protecting participant safety, and data analysis, presentation, publication, and dissemination of results. She will lead weekly team meetings and bi□weekly safety meetings for the technical pilot and RCT; she will also serve as the primary liaison with the DSMB for the RCT. Dr. Buchbinder will serve as primary liaison with the NIH and will oversee all budgetary issues for these studies.

2. 0.60 2232 – Sr. Physician Specialist: Albert Liu 12,798 Annual Salary \$189,600 x 0.60 FTE for 12 months = 9,480 Mandatory Fringe Benefits (@ 35%) = 3,318

Albert Liu as Co-Investigator (Co-PI) will be responsible for overseeing technology development with Alto Pharmacy, data management for all the studies, and assisting with scientific design of research protocols. He will maintain frequent contact with Dr. Buchbinder and the other Co $\Box$ Investigators through in $\Box$ person meetings, conference calls, e $\Box$ mail, and drafting and presenting emerging findings of the research. He will also work closely with the research team in data analysis, manuscript preparation, and dissemination of results.

	Total Salaries Total Fringe	\$42,660 \$14,931
	TOTAL PERSONNEL:	\$57,591
C.	TRAVEL	\$0
D.	EQUIPMENT	\$0
E.	MATERIALS AND SUPPLIES	\$0
F.	CONTRACTUAL	\$0
G.	OTHER	\$0

		TOTAL DIRECT COSTS	\$ <b>57,59</b> 1
Ē	I.	INDIRECT COSTS (25% of Total Personnel)	\$14,398
		TOTAL BUDGET:	\$71,989

.

April 1, 2020 – March 31, 2021

## A. PERSONNELB. MANDATORY FRINGE

 1.
 2.40 0943 - Manager VIII : Susan Buchbinder
 51,192

 Annual Salary \$189,600 x 2.4 FTE for 12 month = 37,920
 51,192

 Mandatory Fringe Benefits (@ 35%) = 13,272

Dr. Buchbinder as Principal Investigator (PI) of this proposal, she will be responsible for theoverall scientific vision and implementation of the specific aims of this study. Dr. Buchbinder will have responsibility for maintaining the proposed study schedule, ensuring quality control over all aspects of the study, protecting participant safety, and data analysis, presentation, publication, and dissemination of results. She will lead weekly team meetings and bi-weekly safety meetings for the technical pilot and RCT; she will also serve as the primary liaison with the DSMB for the RCT. Dr. Buchbinder will serve as primary liaison with the NIH and will oversee all budgetary issues for these studies.

 2.
 1.20 2232 - Sr. Physician Specialist: Albert Liu
 25,596

 Annual Salary \$189,600 x 1.20 FTE for 12 month = 18,960
 Mandatory Fringe Benefits (@ 35%) = 6,636

Dr. Cohen will be responsible for the overall scientific, operational, and administrative aspects of the study at San Francisco City Clinic, which will enroll MSM on PreP. Dr Cohen will be responsible for study implementation, enrollment and retention, data collection, evaluation and reporting, clinical management of study participants, and quality management.

	Total Salaries Total Fringe	\$56,880 \$19,908	
	TOTAL PERSONNEL:	\$76,788	
C.	TRAVEL	\$0	
D.	EQUIPMENT	\$0	
E.	MATERIALS AND SUPPLIES	\$0	
F.	CONTRACTUAL	\$0	
G.	OTHER	\$0	

	TOTAL DIRECT COSTS	\$76,788
н.	INDIRECT COSTS (25% of Total Personnel)	\$19,197
	TOTAL BUDGET:	\$95,985

April 1, 2021 – March 31, 2022

93,123

## A. PERSONNELB. MANDATORY FRINGE

1. 4.20 0943 – Manager VIII : Susan Buchbinder Annual Salary \$199,300 x 4.2 FTE for 12 month = 69,755 Mandatory Fringe Benefits (@ 33.5%) = 23,368

Dr. Buchbinder as Principal Investigator (PI) of this proposal, she will be responsible for the overall scientific vision and implementation of the specific aims of this study. Dr. Buchbinder will have responsibility for maintaining the proposed study schedule, ensuring quality control over all aspects of the study, protecting participant safety, and data analysis, presentation, publication, and dissemination of results. She will lead weekly team meetings and bi-weekly safety meetings for the technical pilot and RCT; she will also serve as the primary liaison with the DSMB for the RCT. Dr. Buchbinder will serve as primary liaison with the NIH and will oversee all budgetary issues for these studies.

 2.
 1.20 2232 - Sr. Physician Specialist: Albert Liu
 26,706

 Annual Salary \$199,300 x 1.20 FTE for 12 month = 19,930
 Mandatory Fringe Benefits (@ 34%) 6,776

Albert Liu as Co-Investigator (Co-PI) will be responsible for overseeing technology development with Alto Pharmacy, data management for all of the studies, and assisting with scientific design of research protocols. He will maintain frequent contact with Dr. Buchbinder and the other Co-Investigators through in-person meetings, conference calls, e-mail, and drafting and presenting emerging findings of the research. He will also work closely with the research team in data analysis, manuscript preparation, and dissemination of results

 3.
 1.20 2232 - Sr. Physician Specialist: Hyman Scott
 13,453

 Annual Salary \$199,300 x 0.60 FTE for 12 month = 9,965
 Mandatory Fringe Benefits (@ 39.76%) 3,488

Hyman Scott as Principal Investigator (PI) will services as Bridge HIV CRS Leader and provide overall operational and quality management oversight of the clinical research and community engagement teams at Bridge HIV. He will co chair the Operations and Performance Steering committee with UCSF CRS leader Dr Luetkemeyer. He will maintain frequent contract with Dr Buchbinder and other CO- Investigators through in person meetings, conference calls, email and drafting and presenting merging research findings.

Total Salaries	\$99,650
Total Fringe	\$33,632
TOTAL PERSONNEL:	\$133,282

C.	TRAVEL	\$0
D.	EQUIPMENT	\$0
E.	MATERIALS AND SUPPLIES	\$0
F.	CONTRACTUAL	\$0
G.	OTHER	\$0
	TOTAL DIRECT COSTS	\$133,282
H.	<b>INDIRECT COSTS (25% of Total Personnel)</b>	\$33,320
	TOTAL BUDGET:	\$166,602

April 1, 2021 – March 31, 2022

93,123

## A. PERSONNELB. MANDATORY FRINGE

1. 0.35 0943 – Manager VIII : Susan Buchbinder Annual Salary \$199,300 x .35 FTE for 12 month = 69,755 Mandatory Fringe Benefits (@ 33.5%) = 23,368

Dr. Buchbinder as Principal Investigator (PI) of this proposal, she will be responsible for the overall scientific vision and implementation of the specific aims of this study. Dr. Buchbinder will have responsibility for maintaining the proposed study schedule, ensuring quality control over all aspects of the study, protecting participant safety, and data analysis, presentation, publication, and dissemination of results. She will lead weekly team meetings and bi-weekly safety meetings for the technical pilot and RCT; she will also serve as the primary liaison with the DSMB for the RCT. Dr. Buchbinder will serve as primary liaison with the NIH and will oversee all budgetary issues for these studies.

 2.
 0.10 2232 - Sr. Physician Specialist: Albert Liu
 26,706

 Annual Salary \$199,300 x .10 FTE for 12 month = 19,930
 Mandatory Fringe Benefits (@ 34%) 6,776

Albert Liu as Co-Investigator (Co-PI) will be responsible for overseeing technology development with Alto Pharmacy, data management for all of the studies, and assisting with scientific design of research protocols. He will maintain frequent contact with Dr. Buchbinder and the other Co-Investigators through in-person meetings, conference calls, e-mail, and drafting and presenting emerging findings of the research. He will also work closely with the research team in data analysis, manuscript preparation, and dissemination of results

 3.
 0.05 2232 - Sr. Physician Specialist: Hyman Scott
 13,453

 Annual Salary \$199,300 x 0.05 FTE for 12 month = 9,965
 Mandatory Fringe Benefits (@ 39.76%) 3,488

Hyman Scott as Principal Investigator (PI) will services as Bridge HIV CRS Leader and provide overall operational and quality management oversight of the clinical research and community engagement teams at Bridge HIV. He will co chair the Operations and Performance Steering committee with UCSF CRS leader Dr Luetkemeyer. He will maintain frequent contract with Dr Buchbinder and other CO- Investigators through in person meetings, conference calls, email and drafting and presenting merging research findings.

TOTAL PERSONNEL:	\$133,282
Total Salaries	\$99,650
Total Fringe	\$33,632

C.	TRAVEL	\$0
D.	EQUIPMENT	\$0
E.	MATERIALS AND SUPPLIES	\$0
F.	CONTRACTUAL	\$0
G.	OTHER	\$0
	TOTAL DIRECT COSTS	\$133,282
H.	<b>INDIRECT COSTS (25% of Total Personnel)</b>	\$33,320
	TOTAL BUDGET:	\$166,602